Progress in Cardiovascular Diseases
Volume 52, Issue 4 , Pages 300-316 , January 2010

Chagas Cardiomyopathy—Where Do We Stand After a Hundred Years?

  • Andréia Biolo

      Affiliations

    • Division of Cardiology, Hospital de Clínicas de Porto Alegre and Faculty of Medicine, Federal University of Rio Grande do Sul, Porto Alegre, RS, Brazil
    • ,
  • Antonio L. Ribeiro

      Affiliations

    • Service of Cardiology, University Hospital and Faculty of Medicine, Federal University of Minas Gerais, Belo Horizonte, MG, Brazil
    • ,
  • Nadine Clausell

      Affiliations

    • Division of Cardiology, Hospital de Clínicas de Porto Alegre and Faculty of Medicine, Federal University of Rio Grande do Sul, Porto Alegre, RS, Brazil
    • Corresponding Author InformationAddress for reprint requests to Nadine Clausell, MD, PhD, Heart Failure and Transplant Unit, Cardiology Division, Hospital de Clínicas de Porto Alegre, Rua Ramiro Barcelos 2350, Sala 2061, 90035-003 Porto Alegre, RS, Brazil.

References 

  1. Chagas C. Uber eine neue Trypanosomiasis des Menschen. Arch Schiffs Tropenhyg. 1909;13:351–353
  2. Prata A. Clinical and epidemiological aspects of Chagas disease. Lancet Infect Dis. 2001;1:92–100
  3. WHO Expert Commitee . Control of Chagas disease. World Health Organ Tech Rep Ser. 2002;905:i-109
  4. Schmunis GA. Epidemiology of Chagas disease in nonendemic countries: the role of international migration. Mem Inst Oswaldo Cruz. 2007;102:75–85
  5. Dobarro D, Gomez-Rubin C, Sanchez-Recalde A, et al. Chagas' heart disease in Europe: an emergent disease?. J Cardiovasc Med (Hagerstown). 2008;9:1263–1267
  6. Bern C, Montgomery SP, Herwaldt BL, et al. Evaluation and treatment of Chagas disease in the United States: a systematic review. JAMA. 2007;298:2171–2181
  7. Bern C, Montgomery SP, Katz L, et al. Chagas disease and the US blood supply. Curr Opin Infect Dis. 2008;21:476–482
  8. Parada H, Carrasco HA, Anez N, et al. Cardiac involvement is a constant finding in acute Chagas' disease: a clinical, parasitological and histopathological study. Int J Cardiol. 1997;60:49–54
  9. Punukollu G, Gowda RM, Khan IA, et al. Clinical aspects of the Chagas' heart disease. Int J Cardiol. 2007;115:279–283
  10. Barretto AC, Ianni BM. The undetermined form of Chagas' heart disease: concept and forensic implications. Sao Paulo Med J. 1995;113:797–801
  11. Marin-Neto JA, Cunha-Neto E, Maciel BC, et al. Pathogenesis of chronic Chagas heart disease. Circulation. 2007;115:1109–1123
  12. Rossi MA, Bestetti RB. The challenge of chagasic cardiomyopathy. The pathologic roles of autonomic abnormalities, autoimmune mechanisms and microvascular changes, and therapeutic implications. Cardiology. 1995;86:1–7
  13. Pereira Barretto AC, Mady C, Arteaga-Fernandez E, et al. Right ventricular endomyocardial biopsy in chronic Chagas' disease. Am Heart J. 1986;111:307–312
  14. Carrasco Guerra HA, Palacios-Pru E, Dagert de Scorza C, et al. Clinical, histochemical, and ultrastructural correlation in septal endomyocardial biopsies from chronic chagasic patients: detection of early myocardial damage. Am Heart J. 1987;113:716–724
  15. Higuchi ML, De Morais CF, Pereira Barreto AC, et al. The role of active myocarditis in the development of heart failure in chronic Chagas' disease: a study based on endomyocardial biopsies. Clin Cardiol. 1987;10:665–670
  16. Tarleton RL. Parasite persistence in the aetiology of Chagas disease. Int J Parasitol. 2001;31:550–554
  17. Jones EM, Colley DG, Tostes S, et al. Amplification of a Trypanosoma cruzi DNA sequence from inflammatory lesions in human chagasic cardiomyopathy. Am J Trop Med Hyg. 1993;48:348–357
  18. Bellotti G, Bocchi EA, de Moraes AV, et al. In vivo detection of Trypanosoma cruzi antigens in hearts of patients with chronic Chagas' heart disease. Am Heart J. 1996;131:301–307
  19. Zhang L, Tarleton RL. Parasite persistence correlates with disease severity and localization in chronic Chagas' disease. J Infect Dis. 1999;180:480–486
  20. Palomino SA, Aiello VD, Higuchi ML. Systematic mapping of hearts from chronic chagasic patients: the association between the occurrence of histopathological lesions and Trypanosoma cruzi antigens. Ann Trop Med Parasitol. 2000;94:571–579
  21. Higuchi ML, Gutierrez PS, Aiello VD, et al. Immunohistochemical characterization of infiltrating cells in human chronic chagasic myocarditis: comparison with myocardial rejection process. Virchows Arch A Pathol Anat Histopathol. 1993;423:157–160
  22. Cunha-Neto E, Bilate AM, Hyland KV, et al. Induction of cardiac autoimmunity in Chagas heart disease: a case for molecular mimicry. Autoimmunity. 2006;39:41–54
  23. Ferrari I, Levin MJ, Wallukat G, et al. Molecular mimicry between the immunodominant ribosomal protein P0 of Trypanosoma cruzi and a functional epitope on the human beta 1-adrenergic receptor. J Exp Med. 1995;182:59–65
  24. Pontes-de-Carvalho L, Santana CC, Soares MB, et al. Experimental chronic Chagas' disease myocarditis is an autoimmune disease preventable by induction of immunological tolerance to myocardial antigens. J Autoimmun. 2002;18:131–138
  25. Cunha-Neto E, Duranti M, Gruber A, et al. Autoimmunity in Chagas disease cardiopathy: biological relevance of a cardiac myosin-specific epitope crossreactive to an immunodominant Trypanosoma cruzi antigen. Proc Natl Acad Sci USA. 1995;92:3541–3545
  26. Cunha-Neto E, Coelho V, Guilherme L, et al. Autoimmunity in Chagas' disease. Identification of cardiac myosin-B13 Trypanosoma cruzi protein crossreactive T cell clones in heart lesions of a chronic Chagas' cardiomyopathy patient. J Clin Invest. 1996;98:1709–1712
  27. Iwai LK, Juliano MA, Juliano L, et al. T-cell molecular mimicry in Chagas disease: identification and partial structural analysis of multiple cross-reactive epitopes between Trypanosoma cruzi B13 and cardiac myosin heavy chain. J Autoimmun. 2005;24:111–117
  28. Ribeiro AL, Gimenez LE, Hernandez CC, et al. Early occurrence of anti-muscarinic autoantibodies and abnormal vagal modulation in Chagas disease. Int J Cardiol. 2007;117:59–63
  29. Amorim DS, Godoy RA, Manco JC, et al. Effects of acute elevation in blood pressure and of atropine on heart rate in Chagas' disease. A preliminary report. Circulation. 1968;38:289–294
  30. Manco JC, Gallo L, Godoy RA, et al. Degeneration of the cardiac nerves in Chagas' disease. Further studies. Circulation. 1969;40:879–885
  31. Marin-Neto JA, Gallo L, Manco JC, et al. Postural reflexes in chronic Chagas's heart disease. Heart rate and arterial pressure responses. Cardiology. 1975;60:343–357
  32. Junqueira Junior LF, Gallo JL, Manco JC, et al. Subtle cardiac autonomic impairment in Chagas' disease detected by baroreflex sensitivity testing. Braz J Med Biol Res. 1985;18:171–178
  33. Guzzetti S, Iosa D, Pecis M, et al. Impaired heart rate variability in patients with chronic Chagas' disease. Am Heart J. 1991;121:1727–1734
  34. Ribeiro AL, Moraes RS, Ribeiro JP, et al. Parasympathetic dysautonomia precedes left ventricular systolic dysfunction in Chagas disease. Am Heart J. 2001;141:260–265
  35. Machado CR, Camargos ER, Guerra LB, et al. Cardiac autonomic denervation in congestive heart failure: comparison of Chagas' heart disease with other dilated cardiomyopathy. Hum Pathol. 2000;31:3–10
  36. Simoes MV, Pintya AO, Bromberg-Marin G, et al. Relation of regional sympathetic denervation and myocardial perfusion disturbance to wall motion impairment in Chagas' cardiomyopathy. Am J Cardiol. 2000;86:975–981
  37. Baroldi G, Oliveira SJ, Silver MD. Sudden and unexpected death in clinically 'silent' Chagas' disease. A hypothesis. Int J Cardiol. 1997;58:263–268
  38. Marin-Neto JA, Maciel BC, Gallo JL, et al. Effect of parasympathetic impairment on the haemodynamic response to handgrip in Chagas's heart disease. Br Heart J. 1986;55:204–210
  39. Rossi MA. Microvascular changes as a cause of chronic cardiomyopathy in Chagas' disease. Am Heart J. 1990;120:233–236
  40. Rossi MA, Goncalves S, Ribeiro-dos-Santos R. Experimental Trypanosoma cruzi cardiomyopathy in BALB/c mice. The potential role of intravascular platelet aggregation in its genesis. Am J Pathol. 1984;114:209–216
  41. Tanowitz HB, Burns ER, Sinha AK, et al. Enhanced platelet adherence and aggregation in Chagas' disease: a potential pathogenic mechanism for cardiomyopathy. Am J Trop Med Hyg. 1990;43:274–281
  42. Tanowitz HB, Kaul DK, Chen B, et al. Compromised microcirculation in acute murine Trypanosoma cruzi infection. J Parasitol. 1996;82:124–130
  43. Marin-Neto JA, Marzullo P, Marcassa C, et al. Myocardial perfusion abnormalities in chronic Chagas' disease as detected by thallium-201 scintigraphy. Am J Cardiol. 1992;69:780–784
  44. Hammermeister KE, Caeiro T, Crespo E, et al. Left ventricular wall motion in patients with Chagas's disease. Br Heart J. 1984;51:70–76
  45. Ministério da Saúde, Secretaria de Vigilancia em Saúde . Brazilian Consensus on Chagas disease. Rev Soc Bras Med Trop. 2005;38(Suppl 3):7–29
  46. Deborggraeve S, Coronado X, Solari A, et al. T. cruzi OligoC-TesT: a simplified and standardized polymerase chain reaction format for diagnosis of Chagas disease. PLoS Negl Trop Dis. 2009;3:e450
  47. Cooley G, Etheridge RD, Boehlke C, et al. High throughput selection of effective serodiagnostics for Trypanosoma cruzi infection. PLoS Negl Trop Dis. 2008;2:e316
  48. Rocha MO, Ribeiro AL, Teixeira MM. Clinical management of chronic Chagas cardiomyopathy. Front Biosci. 2003;8:e44–e54
  49. Ribeiro AL, Rocha MO. Indeterminate form of Chagas disease: considerations about diagnosis and prognosis. Rev Soc Bras Med Trop. 1998;31:301–314
  50. Dias JC. The indeterminate form of human chronic Chagas' disease. A clinical epidemiological review. Rev Soc Bras Med Trop. 1989;22:147–156
  51. Maguire JH, Hoff R, Sherlock I, et al. Cardiac morbidity and mortality due to Chagas' disease: prospective electrocardiographic study of a Brazilian community. Circulation. 1987;75:1140–1145
  52. Rocha MO, Teixeira MM, Ribeiro AL. An update on the management of Chagas cardiomyopathy. Expert Rev Anti Infect Ther. 2007;5:727–743
  53. Rassi A, Rassi A, Little WC. Chagas' heart disease. Clin Cardiol. 2000;23:883–889
  54. Rassi A, Rassi A, Rassi SG. Predictors of mortality in chronic Chagas disease: a systematic review of observational studies. Circulation. 2007;115:1101–1108
  55. Marin-Neto JA, Andrade ZA. Why is there predominance of right heart failure in Chagas' disease?. Arq Bras Cardiol. 1991;57:181–183
  56. Nunes MC, Barbosa MM, Brum VA, et al. Morphofunctional characteristics of the right ventricle in Chagas' dilated cardiomyopathy. Int J Cardiol. 2004;94:79–85
  57. Barros MV, Machado FS, Ribeiro AL, et al. Detection of early right ventricular dysfunction in Chagas' disease using Doppler tissue imaging. J Am Soc Echocardiogr. 2002;15:1197–1201
  58. Marin-Neto JA, Marzullo P, Sousa AC, et al. Radionuclide angiographic evidence for early predominant right ventricular involvement in patients with Chagas' disease. Can J Cardiol. 1988;4:231–236
  59. Nunes MD, Rocha MO, Ribeiro AL, et al. Right ventricular dysfunction is an independent predictor of survival in patients with dilated chronic Chagas' cardiomyopathy. Int J Cardiol. 2008;127:353–359
  60. Barros MV, Machado FS, Ribeiro AL, et al. Diastolic function in Chagas' disease: an echo and tissue Doppler imaging study. Eur J Echocardiogr. 2004;5:182–188
  61. Nunes MC, Barbosa MM, Ribeiro AL, et al. Left atrial volume provides independent prognostic value in patients with Chagas cardiomyopathy. J Am Soc Echocardiogr. 2009;22:82–88
  62. Rassi A, Rassi SG, Rassi A. Sudden death in Chagas' disease. Arq Bras Cardiol. 2001;76:75–96
  63. Martinelli FM, De Siqueira SF, Moreira H, et al. Probability of occurrence of life-threatening ventricular arrhythmias in Chagas' disease versus non-Chagas' disease. Pacing Clin Electrophysiol. 2000;23:1944–1946
  64. Carrasco HA, Guerrero L, Parada H, et al. Ventricular arrhythmias and left ventricular myocardial function in chronic chagasic patients. Int J Cardiol. 1990;28:35–41
  65. Sternick EB, Martinelli M, Sampaio R, et al. Sudden cardiac death in patients with Chagas heart disease and preserved left ventricular function. J Cardiovasc Electrophysiol. 2006;17:113–116
  66. Mota EA, Guimaraes AC, Santana OO, et al. A nine year prospective study of Chagas' disease in a defined rural population in northeast Brazil. Am J Trop Med Hyg. 1990;42:429–440
  67. de Paola AA, Gomes JA, Terzian AB, et al. Ventricular tachycardia during exercise testing as a predictor of sudden death in patients with chronic chagasic cardiomyopathy and ventricular arrhythmias. Br Heart J. 1995;74:293–295
  68. Rassi A, Rassi A, Little WC, et al. Development and validation of a risk score for predicting death in Chagas' heart disease. N Engl J Med. 2006;355:799–808
  69. Ribeiro AL, Cavalvanti PS, Lombardi F, et al. Prognostic value of signal-averaged electrocardiogram in Chagas disease. J Cardiovasc Electrophysiol. 2008;19:502–509
  70. Ribeiro AL. Eletrocardiografia na doença de Chagas. Rev Soc Bras Med Trop. 1994;27:52–54
  71. Benchimol-Barbosa PR, Barbosa-Filho J. Atrial mechanical remodeling and new onset atrial fibrillation in chronic Chagas' heart disease. Int J Cardiol. 2007;127:e113–e115
  72. Espinosa RA, Pericchi LR, Carrasco HA, et al. Prognostic indicators of chronic chagasic cardiopathy. Int J Cardiol. 1991;30:195–202
  73. Ribeiro AL, Rocha MO, Barros MV, et al. A narrow QRS does not predict a normal left ventricular function in Chagas' disease. Pacing Clin Electrophysiol. 2000;23:2014–2017
  74. Ribeiro AL, Lombardi F, Colosimo EA, et al. Risk stratification in Chagas disease: further improvements are needed. J Cardiovasc Electrophysiol. 2008;19:E41–E43
  75. Rincon LG, Rocha MO, Pires MT, et al. Clinical profile of Chagas and non-Chagas' disease patients with cardiac pacemaker. Rev Soc Bras Med Trop. 2006;39:245–249
  76. Mendoza I, Moleiro F, Marques J. Sudden death in Chagas' disease. Arq Bras Cardiol. 1992;59:3–4
  77. Nunes MC, Barbosa MM, Rocha MO. Peculiar aspects of cardiogenic embolism in patients with Chagas' cardiomyopathy: a transthoracic and transesophageal echocardiographic study. J Am Soc Echocardiogr. 2005;18:761–767
  78. Carod-Artal FJ, Vargas AP, Horan TA, et al. Chagasic cardiomyopathy is independently associated with ischemic stroke in Chagas disease. Stroke. 2005;36:965–970
  79. Nunes MC, Barbosa MM, Ribeiro AL, et al. Ischemic cerebrovascular events in patients with Chagas cardiomyopathy: a prospective follow-up study. J Neurol Sci. 2009;278:96–101
  80. Carod-Artal FJ, Vargas AP, Melo M, et al. American trypanosomiasis (Chagas' disease): an unrecognised cause of stroke. J Neurol Neurosurg Psychiatry. 2003;74:516–518
  81. Bestetti RB, Ariolli MT, do Carmo JL, et al. Clinical characteristics of acute myocardial infarction in patients with Chagas' disease. Int J Cardiol. 1992;35:371–376
  82. Barros MV, Costa Rocha MO, Ribeiro AL, et al. Tissue Doppler imaging enables the identification of diastolic dysfunction of pseudonormal pattern in Chagas' disease. J Am Soc Echocardiogr. 2001;14:353–359
  83. Barros MV, Rocha MO, Ribeiro AL, et al. Doppler tissue imaging to evaluate early myocardium damage in patients with undetermined form of Chagas' disease and normal echocardiogram. Echocardiography. 2001;18:131–136
  84. Barros MV, Ribeiro AL, Machado FS, et al. Doppler tissue imaging to assess systolic function in Chagas' disease. Arq Bras Cardiol. 2003;80:36–40
  85. Vinicius Lins BM, Otavio Da Costa RM, Luiz Pinho RA, et al. Tissue Doppler imaging in the evaluation of the regional diastolic function in Chagas' disease. Eur J Echocardiogr. 2001;2:94–99
  86. Silva CE, Ferreira LD, Peixoto LB, et al. Evaluation of segmentary contractility in Chagas' disease by using the integral of the myocardial velocity gradient (myocardial strain) obtained through tissue Doppler echocardiography. Arq Bras Cardiol. 2005;84:285–291
  87. Carrasco HA, Parada H, Guerrero L, et al. Prognostic implications of clinical, electrocardiographic and hemodynamic findings in chronic Chagas' disease. Int J Cardiol. 1994;43:27–38
  88. Mady C, Cardoso RH, Barretto AC, et al. Survival and predictors of survival in patients with congestive heart failure due to Chagas' cardiomyopathy. Circulation. 1994;90:3098–3102
  89. Salles G, Xavier S, Sousa A, et al. Prognostic value of QT interval parameters for mortality risk stratification in Chagas' disease: results of a long-term follow-up study. Circulation. 2003;108:305–312
  90. Viotti R, Vigliano C, Lococo B, et al. Clinical predictors of chronic chagasic myocarditis progression. Rev Esp Cardiol. 2005;58:1037–1044
  91. Perez AA, Ribeiro AL, Barros MV, et al: Value of the radiological study of the thorax for diagnosing left ventricular dysfunction in Chagas' disease. Arq Bras Cardiol 2003;80:208-213, 202-207.
  92. Barbosa MM, Nunes MD, Ribeiro AL, et al. N-terminal proBNP levels in patients with Chagas disease: a marker of systolic and diastolic dysfunction of the left ventricle. Eur J Echocardiogr. 2006;8:204–212
  93. Ribeiro AL, dos Reis AM, Barros MV, et al. Brain natriuretic peptide and left ventricular dysfunction in Chagas' disease. Lancet. 2002;360:461–462
  94. Ribeiro AL, Reis AM, Teixeira MM, et al. Brain natriuretic peptide in Chagas' disease: further insights. Lancet. 2003;362:333
  95. Ribeiro AL, Teixeira MM, Reis AM, et al. Brain natriuretic peptide based strategy to detect left ventricular dysfunction in Chagas disease: a comparison with the conventional approach. Int J Cardiol. 2006;109:34–40
  96. Talvani A, Rocha MO, Cogan J, et al. Brain natriuretic peptide and left ventricular dysfunction in chagasic cardiomyopathy. Mem Inst Oswaldo Cruz. 2004;99:645–649
  97. Talvani A, Rocha MO, Cogan J, et al. Brain natriuretic peptide measurement in Chagas heart disease: marker of ventricular dysfunction and arrhythmia. Int J Cardiol. 2005;100:503–504
  98. Oliveira BM, Botoni FA, Ribeiro AL, et al. Correlation between BNP levels and Doppler echocardiographic parameters of left ventricle filling pressure in patients with chagasic cardiomyopathy. Echocardiography. 2009;26:521–527
  99. Grupi CJ, Moffa PJ, Barbosa SA, et al. Holter monitoring in Chagas' heart disease. Sao Paulo Med J. 1995;113:835–840
  100. Martinelli FM, Sosa E, Nishioka S, et al. Clinical and electrophysiologic features of syncope in chronic chagasic heart disease. J Cardiovasc Electrophysiol. 1994;5:563–570
  101. Ribeiro AL, Lombardi F, Sousa MR, et al. Power-law behavior of heart rate variability in Chagas' disease. Am J Cardiol. 2002;89:414–418
  102. Ribeiro AL, Lombardi F, Sousa MR, et al. Vagal dysfunction in Chagas disease. Int J Cardiol. 2005;103:225–226
  103. Ribeiro AL, Schmidt G, Sousa MR, et al. Heart rate turbulence in Chagas disease. Pacing Clin Electrophysiol. 2003;26:406–410
  104. Tundo F, Lombardi F, Rocha MC, et al. Heart rate turbulence and left ventricular ejection fraction in Chagas disease. Europace. 2005;7:197–203
  105. Leite LR, Fenelon G, Simoes A, et al. Clinical usefulness of electrophysiologic testing in patients with ventricular tachycardia and chronic chagasic cardiomyopathy treated with amiodarone or sotalol. J Cardiovasc Electrophysiol. 2003;14:567–573
  106. Silva RM, Tavora MZ, Gondim FA, et al. Predictive value of clinical and electrophysiological variables in patients with chronic chagasic cardiomyopathy and nonsustained ventricular tachycardia. Arq Bras Cardiol. 2000;75:33–47
  107. Rocha AL, Rocha MO, Teixeira BO, et al. Chronotropic-metabolic index in Chagas' disease. Rev Soc Bras Med Trop. 2005;38:373–376
  108. Rocha AL, Lombardi F, Costa Rocha MO, et al. Chronotropic incompetence and abnormal autonomic modulation in ambulatory Chagas disease patients. Ann Noninvasive Electrocardiol. 2006;11:3–11
  109. Simoes MV, Ayres EM, Santos JL, et al. Detection of myocardial ischemia in chronic Chagas disease patients with atypic precordial pain by exercise and Holter tests. Arq Bras Cardiol. 1993;60:315–319
  110. Rochitte CE, Nacif MS, Oliveira Junior AC, et al. Cardiac magnetic resonance in Chagas' disease. Artif Organs. 2007;31:259–267
  111. Rochitte CE, Oliveira PF, Andrade JM, et al. Myocardial delayed enhancement by magnetic resonance imaging in patients with Chagas' disease: a marker of disease severity. J Am Coll Cardiol. 2005;46:1553–1558
  112. Kuschnir E, Sgammini H, Castro R, et al. Evaluation of cardiac function by radioisotopic angiography, in patients with chronic Chagas cardiopathy. Arq Bras Cardiol. 1985;45:249–256
  113. Viotti R, Vigliano C, Lococo B, et al. Long-term cardiac outcomes of treating chronic Chagas disease with benznidazole versus no treatment: a nonrandomized trial. Ann Intern Med. 2006;144:724–734
  114. Benchimol Barbosa PR. Noninvasive prognostic markers for cardiac death and ventricular arrhythmia in long-term follow-up of subjects with chronic Chagas' disease. Braz J Med Biol Res. 2007;40:167–178
  115. Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation. 2005;112:e154–e235
  116. Bocchi EA, Vilas-Boas F, Perrone S, et al. Latin American guidelines for the assessment and management of decompensated heart failure. Arq Bras Cardiol. 2005;85(Suppl 3):49–94
  117. Salles GF, Xavier SS, Sousa AS, et al. T-wave axis deviation as an independent predictor of mortality in chronic Chagas' disease. Am J Cardiol. 2004;93:1136–1140
  118. Rocha MO, Ribeiro AL. A risk score for predicting death in Chagas' heart disease. N Engl J Med. 2006;355:2488–2489
  119. Kalil J, Cunha-Neto E. Autoimmunity in Chagas disease cardiomyopathy: fulfilling the criteria at last?. Parasitol Today. 1996;12:396–399
  120. Cunha-Neto E, Teixeira PC, Nogueira LG, et al. New concepts on the pathogenesis of chronic Chagas cardiomyopathy: myocardial gene and protein expression profiles. Rev Soc Bras Med Trop. 2006;39(Suppl 3):59–62
  121. Jones EM, Colley DG, Tostes S, et al. A Trypanosoma cruzi DNA sequence amplified from inflammatory lesions in human chagasic cardiomyopathy. Trans Assoc Am Physicians. 1992;105:182–189
  122. de Andrade AL, Zicker F, de Oliveira RM, et al. Randomised trial of efficacy of benznidazole in treatment of early Trypanosoma cruzi infection. Lancet. 1996;348:1407–1413
  123. Rassi A, Rassi A, Rassi GG. Fase aguda. In:  Brener Z,  Andrade ZA,  Barral-Netto M editor. Trypanosoma cruzi e doença de Chagas. Brazil: Guanabara-Koogan; 2000;p. 231–245
  124. Sosa ES, Segura EL, Ruiz AM, et al. Efficacy of chemotherapy with benznidazole in children in the indeterminate phase of Chagas' disease. Am J Trop Med Hyg. 1998;59:526–529
  125. Villar JC, Marin-Neto JA, Ebrahim S, et al. Trypanocidal drugs for chronic asymptomatic Trypanosoma cruzi infection. Cochrane Database Syst Rev. 2002;CD003463
  126. Yun O, Lima MA, Ellman T, et al. Feasibility, drug safety, and effectiveness of etiological treatment programs for Chagas disease in Honduras, Guatemala, and Bolivia: 10-year experience of Medecins Sans Frontieres. PLoS Negl Trop Dis. 2009;3:e488
  127. Viotti R, Vigliano C, Lococo B, et al. Side effects of benznidazole as treatment in chronic Chagas disease: fears and realities. Expert Rev Anti Infect Ther. 2009;7:157–163
  128. Franco-Paredes C, Bottazzi ME, Hotez PJ. The unfinished public health agenda of Chagas disease in the era of globalization. PLoS Negl Trop Dis. 2009;3:e470
  129. Ribeiro I, Sevcsik AM, Alves F, et al. New, improved treatments for Chagas disease: from the r and d pipeline to the patients. PLoS Negl Trop Dis. 2009;3:e484
  130. Marin-Neto JA, Rassi A, Morillo CA, et al. Rationale and design of a randomized placebo-controlled trial assessing the effects of etiologic treatment in Chagas' cardiomyopathy: the BENznidazole Evaluation For Interrupting Trypanosomiasis (BENEFIT). Am Heart J. 2008;156:37–43
  131. Marin-Neto JA, Rassi A, Avezum A, et al. The BENEFIT trial: testing the hypothesis that trypanocidal therapy is beneficial for patients with chronic Chagas heart disease. Mem Inst Oswaldo Cruz. 2009;104:319–324
  132. Roberti RR, Martinez EE, Andrade JL, et al. Chagas cardiomyopathy and captopril. Eur Heart J. 1992;13:966–970
  133. Szajnbok FE, Barretto AC, Mady C, et al. Beneficial effects of enalapril on the diastolic ventricular function in Chagas myocardiopathy. Arq Bras Cardiol. 1993;60:273–278
  134. Davila DF, Angel F, Arata dB, et al. Effects of metoprolol in chagasic patients with severe congestive heart failure. Int J Cardiol. 2002;85:255–260
  135. Botoni FA, Poole-Wilson PA, Ribeiro AL, et al. A randomized trial of carvedilol after renin-angiotensin system inhibition in chronic Chagas cardiomyopathy. Am Heart J. 2007;153:544–548
  136. Braga JC, Reis F, Aras R, et al. Clinical and therapeutics aspects of heart failure due to Chagas disease. Arq Bras Cardiol. 2006;86:297–302
  137. Bestetti RB, Muccillo G. Clinical course of Chagas' heart disease: a comparison with dilated cardiomyopathy. Int J Cardiol. 1997;60:187–193
  138. Bestetti RB, Sales-Neto VN, Pinto LZ, et al. Effects of long term metoprolol administration on the electrocardiogram of rats infected with T cruzi. Cardiovasc Res. 1990;24:521–527
  139. Bestetti RB, Theodoropoulos TA, Cardinalli-Neto A, et al. Treatment of chronic systolic heart failure secondary to Chagas heart disease in the current era of heart failure therapy. Am Heart J. 2008;156:422–430
  140. Botoni FA, Poole-Wilson PA, Ribeiro AL, et al. Treating Chagas' cardiomyopathy patients with chronic heart failure. Am Heart J. 2007;e33:154
  141. Khoury AM, Davila DF, Bellabarba G, et al. Acute effects of digitalis and enalapril on the neurohormonal profile of chagasic patients with severe congestive heart failure. Int J Cardiol. 1996;57:21–29
  142. Bestetti RB, Rossi MA. A rationale approach for mortality risk stratification in Chagas' heart disease. Int J Cardiol. 1997;58:199–209
  143. de Sousa AS, Xavier SS, de Freitas GR, et al. Prevention strategies of cardioembolic ischemic stroke in Chagas' disease. Arq Bras Cardiol. 2008;91:306–310
  144. Rassi JA, Gabriel RA, Gabriel RS, et al. Ventricular arrhythmia in Chagas disease. Diagnostic, prognostic, and therapeutic features. Arq Bras Cardiol. 1995;65:377–387
  145. Rosa RF, Neto AS, Franken RA. Chagas' disease and the use of implantable cardioverter-defibrillators in Brazil. Am J Geriatr Cardiol. 2006;15:372–376
  146. Cardinalli-Neto A, Greco OT, Bestetti RB. Automatic implantable cardioverter-defibrillators in Chagas' heart disease patients with malignant ventricular arrhythmias. Pacing Clin Electrophysiol. 2006;29:467–470
  147. Cardinalli-Neto A, Bestetti RB, Cordeiro JA, et al. Predictors of all-cause mortality for patients with chronic Chagas' heart disease receiving implantable cardioverter defibrillator therapy. J Cardiovasc Electrophysiol. 2007;18:1236–1240
  148. Doval HC, Nul DR, Grancelli HO, et al. Randomised trial of low-dose amiodarone in severe congestive heart failure. Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina (GESICA). Lancet. 1994;344:493–498
  149. Bocchi EA, Fiorelli A. The Brazilian experience with heart transplantation: a multicenter report. J Heart Lung Transplant. 2001;20:637–645
  150. Parra AV, Rodrigues V, Cancella S, et al. Impact of socioeconomic status on outcome of a Brazilian heart transplant recipients cohort. Int J Cardiol. 2008;125:142–143
  151. Theodoropoulos TA, Bestetti RB, Otaviano AP, et al. Predictors of all-cause mortality in chronic Chagas' heart disease in the current era of heart failure therapy. Int J Cardiol. 2008;128:22–29
  152. Bocchi EA, Fiorelli A. The paradox of survival results after heart transplantation for cardiomyopathy caused by Trypanosoma cruzi. First Guidelines Group for Heart Transplantation of the Brazilian Society of Cardiology. Ann Thorac Surg. 2001;71:1833–1838
  153. Sartori AM, Ibrahim KY, Nunes Westphalen EV, et al. Manifestations of Chagas disease (American trypanosomiasis) in patients with HIV/AIDS. Ann Trop Med Parasitol. 2007;101:31–50
  154. Sartori AM, Neto JE, Nunes EV, et al. Trypanosoma cruzi parasitemia in chronic Chagas disease: comparison between human immunodeficiency virus (HIV)–positive and HIV-negative patients. J Infect Dis. 2002;186:872–875
  155. de Carvalho VB, Sousa EF, Vila JH, et al. Heart transplantation in Chagas' disease. 10 years after the initial experience. Circulation. 1996;94:1815–1817
  156. Bocchi EA, Bellotti G, Mocelin AO, et al. Heart transplantation for chronic Chagas' heart disease. Ann Thorac Surg. 1996;61:1727–1733
  157. Bestetti RB, Souza TR, Lima MF, et al. Effects of a mycophenolate mofetil–based immunosuppressive regimen in Chagas' heart transplant recipients. Transplantation. 2007;84:441–442
  158. de Souza MM, Franco M, Almeida DR, et al. Comparative histopathology of endomyocardial biopsies in chagasic and non-chagasic heart transplant recipients. J Heart Lung Transplant. 2001;20:534–543
  159. Fiorelli AI, Stolf NA, Honorato R, et al. Later evolution after cardiac transplantation in Chagas' disease. Transplant Proc. 2005;37:2793–2798
  160. Rassi A, Dias JC, Marin-Neto JA, et al. Challenges and opportunities for primary, secondary, and tertiary prevention of Chagas disease. Heart. 2009;95:524–534
  161. Senior K. Chagas disease: moving towards global elimination. Lancet Infect Dis. 2007;7:572
  162. Centers for Disease Control and Prevention . Blood donor screening for Chagas disease: United States, 2006-2007. MMWR Morb Mortal WklyRep. 2007;56:141–143

 Statement of Conflict of Interest: see page 311.

PII: S0033-0620(09)00098-X

doi: 10.1016/j.pcad.2009.11.008

Progress in Cardiovascular Diseases
Volume 52, Issue 4 , Pages 300-316 , January 2010

Article Tools

* Image Usage & Resolution